海外の治験の状況「COVID-19」での検索結果
40件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- Risk of Positive Doping Tests Following Ingestion of Supplements Contaminated With Trace Quantities of Nandrolone Metabolites
- Positive Doping Tests in Sports
- United Kingdom
- 2008-05-20
Not recruiting
- Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
- Influenza, Human
- Belgium, Germany, Spain
- 2018-09-27
Not Recruiting
- A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate (MenACWY-TT) vaccine versus one subcutaneous dose of MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years - MenACWY-TT-009
- Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and Y
- Belgium
- 2005-07-27
Not Recruiting
- A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (=66 years) previously vaccinated in the FluAS25-004 clinical trial with the same candidate vaccine. Fluarix™ (known as a-Rix in Belgium) administered in young (19-42 years) and elderly (=66 years) adults will be used as reference. - FluAS25-008 EXT:003 Y2
- Immunization against influenza in male and female subjects aged 66 years and older.
- Belgium
- 2007-08-16
Not recruiting
- Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
- Acute Myocardial Infarction;Acute Myocardial Infarction;Acute Myocardial Infarction;Acute Myocardial Infarction
- Germany
- 2015-06-25
Not Recruiting
- A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate vaccine H5N1 A/Vietnam/1194/2004 containing 3.8, 7.5, 15 or 30 µg HA, adjuvanted or not with AS03. - H5N1-015
- Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines. Candidate ‘pandemic-like’ vaccines must be developed and tested in clinical trials to determine the best vaccination schedule.
- Belgium
- 2007-07-03
Not Recruiting
- A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 03, incorporating Protocol Amendment 04 (V1.0, Date 26-Aug-2008), Protocol Amendment 05 (V1.0, Date 20-Nov-2008), and Protocol Amendment 06 (V1.0, date 05-Jan-2009). + Protocol Amendment 07, country specific - Germany (V1.0, date 19-Dec-2008). + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (V1.0, Date 26-Nov-2007).
- MELANOMA MedDRA version: 9.1 Level: LLT Classification code 10025670 Term: Malignant melanoma stage III MedDRA version: 9.1 Level: LLT Classification code 10025671 Term: Malignant melanoma stage IV
- Denmark, France, Germany, Italy
- 2008-01-17
Not Recruiting
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer Revised Protocol 02 incorporating Amendment 03 (version 4.0 dated 01-Sep-09) + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08)
- Advanced Non-Small Cell Lung Cancer MedDRA version: 9.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS
- France, Germany, Italy, Spain
- 2008-08-07
Not Recruiting
- A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate. Revised Protocol 05, incorporating Administrative Letters 01, 02, 03 and 04 and Amendments 01, 02, 03 (v1.0, dated 28-Feb-2008) and 04 (v1.0, dated 19-Dec-2008)
- Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib Mesylate
- Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Ireland, Italy, Spain, Sweden, United Kingdom
- 2005-06-13